Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378151 | 0.99 | ALDH1A1 (0.44) | ALDH1A1AOC3G6PDDPP4CYP11B1 | |
| SCHEMBL2211748 | 0.93 | PPARG (0.47) | AOC3G6PDDPP4CYP11B1CYP11B2 | |
| SCHEMBL2215682 | 0.92 | PPARG (0.48) | AOC3G6PDDPP4CYP11B1CYP11B2 | |
| SCHEMBL2212909 | 0.91 | PDE3B (0.45) | ALDH1A1AOC3G6PDCYP11B1CYP11B2 | |
| SCHEMBL2213244 | 0.90 | AOC3 (0.43) | ALDH1A1AOC3G6PDCYP11B1CYP11B2 | |
| SCHEMBL2215788 | 0.90 | PDE3B (0.45) | ALDH1A1AOC3G6PDCYP11B1CYP11B2 | |
| SCHEMBL2211572 | 0.90 | G6PD (0.46) | AOC3G6PDDPP4CYP11B1CYP11B2 | |
| SCHEMBL2818911 | 0.90 | AOC3 (0.41) | AOC3G6PDCYP11B1CYP11B2AKT1 | |
| SCHEMBL2213751 | 0.90 | AOC3 (0.42) | ALDH1A1AOC3G6PDCYP11B1CYP11B2 | |
| SCHEMBL7108384 | 0.89 | DPP4 (0.40) | ALDH1A1G6PDDPP4MAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474415-B1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | claimed |
| US-7683081-B2 | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | claimed |
| US-6962932-B2 | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-08 | — | — | US | claimed |
| EP-1474415-B1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7683081-B2 | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6962932-B2 | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1474415-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | Schering Aktiengesellschaft (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003068766-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, NFATC1, ICOS | ALDH1A1 1382/4885AOC3 2681/4885G6PD 1355/4885 |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, ICOS, NFATC1 | ALDH1A1 937/4885AOC3 1556/4885G6PD 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.